N-Acetyl Cysteine (NAC) for Reduced Oxidative Stress

NAC is one of the few supplements with a genuine, mechanistically clean claim on oxidative stress: it supplies the rate-limiting substrate for glutathione, the body's principal intracellular antioxidant.

Trials consistently show that oral NAC raises glutathione and lowers oxidative stress markers such as malondialdehyde and 8-OHdG, particularly in populations where glutathione is depleted - chronic kidney disease, COPD, diabetes, infertility, chronic infection and heavy oxidative load. Its intravenous use in paracetamol poisoning is the clinical proof of the mechanism. The honest limitation is that lowering a biomarker is not the same as improving health. In healthy, well-nourished people glutathione is already adequate, benefit is small, and there is some evidence that blunting exercise-induced oxidative signalling can reduce training adaptation.

Glutathione is a tripeptide of glutamate, glycine and cysteine. Cysteine availability limits its synthesis, and free cysteine is unstable and toxic in high concentrations, so the body cannot simply be given cysteine. NAC is an acetylated, stable delivery form that is deacetylated intracellularly to supply cysteine directly to the synthesis pathway.

Restored glutathione supports glutathione peroxidase in neutralising hydrogen peroxide and lipid peroxides, and glutathione S-transferases in conjugating reactive electrophiles for excretion. NAC also has a direct but minor thiol-based scavenging action and can break disulphide bonds, which explains its mucolytic use. The key implication is that NAC only helps when glutathione synthesis is substrate-limited. Where it is not, adding cysteine changes little.

Doses in the antioxidant literature cluster in a fairly narrow band.

There are currently no studies linked to this pairing in our library, so no study list is shown.

Across randomised trials in oxidative-stress-heavy conditions, NAC at 600 to 1,800 mg daily reliably raises glutathione and lowers lipid peroxidation markers, with meta-analytic support in chronic kidney disease, COPD, diabetes and male infertility. The biomarker effect is one of the more reproducible findings in the supplement literature. Certainty falls when the endpoint becomes clinical. Trials are heterogeneous in dose, duration and marker choice, populations are usually diseased rather than healthy, and translation from marker improvement to outcomes such as event rates or mortality is largely unproven. Assume mechanism-level confidence, not outcome-level confidence.

Oral NAC is well tolerated. Nausea, bloating and diarrhoea are the usual complaints, more common above 1,800 mg daily, and the sulphurous smell puts some people off. Rash and, rarely, bronchospasm can occur, mostly with intravenous use.

More is not better. Antioxidant supplementation at high dose can be counterproductive, since reactive oxygen species serve as signalling molecules in immune function, insulin sensitivity and training adaptation. Stay within conventional doses rather than escalating, and avoid stacking several high-dose antioxidants at once.

NAC has a small number of clinically meaningful interactions.

No studies are currently linked to this pairing, so no reference list is available. This section will populate as evidence is added to the library.